An open-label, randomized and multi-center clinical trial to evaluate the efficacy of silibinin in preventing drug-induced liver injury

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 3, 2015, Pages 4320-4327

  Gu, Jin ^a   Tang, Shen Jie ^b   Tan, Shou Yong ^c   Wu, Qi ^d   Zhang, Xia ^e   Liu, Cun Xu ^f   Gao, Xu Sheng ^g   Yuan, Bao Dong ^h   Han, Li Jun ⁱ   Gao, Ai Ping ^j   Wu, Mei Ying ^k   Huang, Li Hua ^l   Ma, Jun ^m   Xiao, He Ping ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Guangzhou Chest Hospital   (China)

^d TIANJIN HAIHE HOSPITAL   (China)

^e NANJING CHEST HOSPITAL   (China)

^f Longtan Hospital of Guangxi Province   (China)

^g Shandong Provincial Chest Hospital   (China)

^h Tuberculosis Institute of Wuhan City   (China)

ⁱ Infectious Disease Hospital of Changchun City   (China)

^j Anhui Province Chest Hospital   (China)

^k The Affiliated Infectious Diseases Hospital of Soochow University   (China)

^l Wuxi Infectious Diseases Hospital   (China)

^m TIANJIN MEDICAL UNIVERSITY   (China)

more..

Author keywords

Drug induced liver injury; Pulmonary tuberculosis; Silibinin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; SILIBININ;

ADULT; ANOREXIA; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERURICEMIA; INCIDENCE; LEUKOPENIA; LIVER FUNCTION TEST; LIVER PROTECTION; LUNG TUBERCULOSIS; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPUTUM CULTURE; SYMPTOM ASSESSMENT; TOXIC HEPATITIS;

EID: 84929347069     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Baghaei P, Tabarsi P, Chitsaz E, Saleh M, Ma-rjani M, Shemirani S, Pooramiri MV, Kazempour M, Farnia P, Fahimi F, Mansouri D and Masjedi M. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. Am J Ther 2010; 17: 17-22.
2. Liu Q, Garner P, Wang Y, Huang B and Smith H. Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health 2008; 8: 365.
3. Cha D, Cheng D, Liu M, Zeng Z, Hu X and Guan W. Analysis of fatty acids in sputum from patients with pulmonary tuberculosis using gas chromatography-mass spectrometry preceded by solid-phase microextraction and post-derivatization on the fiber. J Chromatogr A 2009; 1216: 1450-1457.
4. Xiao T. Handbook for diagnosis and treatment of anti-TB drug-induced adverse reactions. People’s Health Publishing House, 2009.
5. Xu X, Wong X, Liu F, Zhang X and Peng W. The clinical investigation of drug induced liver injury and its influencing factors analysis. Chinese Journal of clinical pharmacology 2014; 30: 216-218.
6. Grant LM and Rockey DC. Drug-induced liver injury. Curr Opin Gastroenterol 2012; 28: 198-202.
7. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC and Wang Y. Reprint of: Ep-idemiological serosurvey of Hepatitis B in China--declining HBV prevalence due to Hepa-titis B vaccination. Vaccine 2013; 31 Suppl 9: J21-28.
8. Saad EI, El-Gowilly SM, Sherhaa MO and Bistawroos AE. Role of oxidative stress and nitric oxide in the protective effects of alpha-lipoic acid and aminoguanidine against isoniazid-rifampicin-induced hepatotoxicity in rats. Food Chem Toxicol 2010; 48: 1869-1875.
9. Xiao H. Controversial over concomitant use of hepatoprotective drugs in anti TB treatment. Chinese Journal of Tuberculosis and Respiratory Diseases 2013; 3: 722-723.
10. Padmapriyadarsini C, Bhavani PK, Tang A, Ku-mar H, Ponnuraja C, Narendran G, Hannah E, Ramesh C, Chandrasekar C, Wanke C and Swaminathan S. Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy. Int J Infect Dis 2013; 17: e1154-1159.
11. Stirnimann G, Kessebohm K and Lauterburg B. Liver injury caused by drugs: an update. Swiss Med Wkly 2010; 140: w13080.
12. Nanashima K, Mawatari T, Tahara N, Higuchi N, Nakaura A, Inamine T, Kondo S, Yanagihara K, Fukushima K, Suyama N, Kohno S and Tsu-kamoto K. Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients. Tuberculosis (Edinb) 2012; 92: 253-259.
13. Sarda P, Sharma SK and Mohan A. Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2009; 129: 64-67.
14. Singla R, Sharma SK and Mohan A. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2010; 132: 81-87.
15. Babalik A, Arda H, Bakirci N, Agca S, Oruc K, Kiziltas S, Cetintas G and Calisir HC. Man-agement of and risk factors related to hepatotoxicity during tuberculosis treatment. Tuberk Toraks 2012; 60: 136-144.